Enabling same-shift antibiotic treatment for sepsis
Sepsis causes 20% of all deaths globally, affecting 5 million people yearly in the EU and US. While a patient can go from symptoms to death in <1 day, finding the infection-causing pathogen can take up to 7 days. The current procedure, blood culturing, requires bacteria to grow up to a million times to reach detection limits.
We developed a lab-on-a-chip solution that isolates pure bacteria from blood in <30 minutes, reaching 10,000x higher sensitivity. Our technology enables same-shift targeted antibiotic treatment, reducing AMR risk, improving clinical outcomes, and saving hospital costs.
The technology is based on more than 15 years of sepsis sample prep research, with a pathway of iterative learning. Several breakthrough, patented technologies have enabled the creation of a turnkey solution that is fast, affordable, and reliable. We are currently working on our first prototype for clinical testing and validating different sample types to expand our portfolio.
